Cash Expected to Fund Operations through the End of 2017 Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical...
PRINCETON, N.J., May 07, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2018 and provided a corporate update. First quarter 2018 and other recent corporate developments include:...
Company Plans to Resubmit Twirla® NDA in Second Quarter of 2019 Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 PRINCETON, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial...
FDA Approved Twirla ® Expected to Reach Wholesalers in the Fourth Quarter of 2020 $93.9 Million in Cash and Cash Equivalents as of March 31, 2020 Management to Host Conference Call at 4:30 PM ET PRINCETON, N.J. , May 05, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....
Prescription Growth Reflects Increasing Demand for Twirla Base of Prescribers Continues to Grow in First Quarter 2021 Growing Distribution Network and Marketing Efforts Expected to Drive Healthcare Provider and Consumer Engagement PRINCETON, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Agile...
Twirla Experienced Another Quarter of Double-Digit Demand Growth in First Quarter 2022 Twirla Business Plan Progressing Company Anticipates Future 2022 Quarterly Operating Expenses to be Lower Management to Host Conference Call Today, Thursday, May 12, 2022 at 4:30 p.m....
Twirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth Quarter 2022 Company Reaffirms Expected Full Year 2023 Net Revenue in Range of $25-$30 Million Management to...
Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available Achieved Gross Revenue Target In Fourth Quarter 2020, Reflecting Initial Stocking of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system Announces Agreement with Sterling Specialty...
